An observational study evaluating the safety of an FDA approved drug, Obizur, in patients with hemophilia A.

What we are studying

There are two cohorts in this study. The first cohort is a prospective arm that will collect data from patients who are treated with Obizur over a period of 180 days. The second cohort is a retrospective arm that will review safety information from patients who have already been treated with Obizur since FDA approval.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Subject has AHA
  • And is being treated/was treated with Obizur
  • Subject is willing and able to provide informed consent
  • Unless informed consent is not required (e.g.
  • Retrospective cohort subjects who are deceased)

What is involved

  • Follow up appointments in prospective cohort

Compensation

None

Contact Information

Study Coordinator
Jennifer Thomas, MHA, BSN, RN
Email
[email protected]
Phone
336 713 6914
Principal Investigator
Katharine Batt, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.